A Phase 1 interventional study of Memantine Hydrochloride and Placebo in Epilepsy, sponsored by Assiut University. Completed at 1 site in Egypt. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2020-06-04.
Sponsored by Assiut University · Phase 1, Interventional, and Treatment
Evaluate the efficacy of memantine on improving the cognitive impairment in patient with epilepsy
Epilepsy is a complex disorder, which involves much more than seizures, encompassing a range of associated comorbid health conditions that can have significant health and quality-of-life implications. Of these comorbidities, cognitive impairment is one of the most common and distressing aspects of epilepsy.
Excito-toxicity, mediated by glutamate acting on N-methyl-D-aspartate (NMDA) receptors in the hippocampus, can cause memory dysfunction in epilepsy .
Memantine is a low-affinity voltage-dependent uncompetitive antagonist of the NMDA-type glutamate receptor . It also has antioxidant property and increases production of brain derived neurotropic factor (BDNF)
1,805 studies on the registry are indexed under Epilepsy; 417 are open to participants now.
This study's enrollment of 100 is above the median of 50 across 1,206 interventional studies indexed under Epilepsy.
Browse Epilepsy studies →Assiut University is the lead sponsor of 4,901 studies on the registry; 2,098 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
included 50 patients who received memantine
Drug: Memantine Hydrochloride
included 50 patients who received placebo
Drug: Placebo
Memantine is a low-affinity voltage-dependent uncompetitive antagonist of the NMDA-type glutamate receptor .Memantine hydrochloride tablet was started at the dose of 5 mg once daily orally, and the same dose was given for 3months and dose is titrated to 10 mg once daily orally for the remaining 3months. Placebo was given once daily orally for6months. Patients were instructed to take the study medication at the same time every day.
Also known as: Memantine
Placebo was given once daily orally for6months. Patients were instructed to take the study medication at the same time every day.
Memory Assessment Scale (MAS)
This comprehensive battery assesses short-term, verbal and visual memory functioning.
Time frame: 1.5years
Wechsler Adult Intelligence Scale (WAIS)
Intelligence quotient (IQ) tests are the primary clinical instruments used to measure adult and adolescent intellience.
Time frame: 1.5years
Brief Visuospatial Memory Test-Revised (BVMT-R)
The current revised version of the BVMT, a visual display of six simple figures arranged in a 2 × 3 matrix on an 8 × 11 booklet is shown to participants for three consecutive 10-second trials.
Time frame: 1.5years
This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assiut University